ArticleJournal of immunology research2026
MicroRNA-382 Is Involved in Acute Kidney Injury via Regulating STAT1 Signaling.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA-382 Is Involved in Acute Kidney Injury via Regulating STAT1 Signaling.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Acute kidney injury (AKI), characterized by inflammation and oxidative stress, is a life-threatening clinical presentation. We previously demonstrated the role of miR-382 in the progression of chronic kidney disease (CKD). However, the role of miR-382 in AKI is unknown. Genetic depletion of miR-382 exacerbated renal dysfunction, histologic lesions, apoptosis of epithelial cells, and oxidative stress in kidneys in ischemia-reperfusion (I/R)- and sepsis-induced AKI. In vitro, downregulation of miR-382 accompanied with activation of phosphorylation of signal transducer and activator of transcription 1 (STAT1) were induced in mouse renal tubular epithelial cells (mTECs) with hypoxia/reoxygenation (H/R) and lipopolysaccharide (LPS) treatments. Colocalization of phosphorylated STAT1 (p-STAT1) and Lotus tetragonolobus lectin (LTL) suggested the activation of STAT1 signaling in renal epithelial after I/R injury (IRI). Overexpression of miR-382 in mTECs abrogated phosphorylation of STAT1, generation of interleukin-6 (Il-6), tumor necrosis factor-α (Tnf-α), and Il-1β as well as reactive oxygen species (ROS) and apoptosis after H/R- and LPS treatments. Additionally, loss of miR-382 was found in isolated macrophages from kidney during I/R-induced AKI. Upregulation of miR-382 in Raw264.7 cells inactivated STAT1 signaling and hindered polarization of M1 macrophages inhibiting Il-6 and inducible nitric oxide synthase (iNos). Inhibition of STAT1 pharmacologically reduced Il-1β, Il-6, and Tnf-α in Raw264.7 after H/R. Taken together, these results demonstrated the protective role of miR-382 in I/R- and sepsis-induced AKI, suggesting miR-382 as a novel therapeutic strategy for AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.